OncoSil Medical can only authorise a shipment of the OncoSil™ System after:
- The license for the treatment facility to receive and hold phosphorous-32 (32P) has been verified by OncoSil Medical
- A training visit has been conducted in which individuals permitted to work as an Authorised Dispenser and Authorised User (and other surgical/procedural personnel as required) have successfully completed the OncoSil Medical Training Program
Getting started with OncoSil™
Certification of treatment facilities and personnel
The OncoSil™ System is to be used in a treatment facility which must hold an appropriate license for the isotope phosphorous-32 (32P) and have an appointed radiation safety officer (RSO) / radiation protection officer (RPO) who will be the primary contact for all matters related to radiation safety.
The OncoSil™ suspension should be prepared within the Nuclear Medicine Department or within a licensed radiopharmacy. Only appropriately licensed personnel, who have been trained in the preparation of the OncoSil™ suspension may prepare the product for implantation.
Contact us now to get started with OncoSil™ in your institution
Who else should take part in the OncoSil Medical Training Program?
As the implantation and handling of OncoSil™ involves a multi-disciplinary team, the following personnel may be expected to undertake the OncoSil Medical Training Program:
- Nuclear medicine personnel (physician, physicists, technologists, radiopharmacist)
- Radiation safety officer (RSO) / radiation protection officer (RPO)
- Radiation, medical and surgical oncologists
- Interventional radiologists
- Endoscopist
- Procedural staff (nurses, anaesthetists)
OncoSil™ in pancreatic cancer
OncoSil™ has been studied in two clinical trials in unresectable locally advanced pancreatic cancer
Publications
Review OncoSil™ publications and conference presentations
OncoSil device
OncoSil™ is a single-use brachytherapy device